Tag Archives: LOXO

Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)

The American Society for Clinical Oncology (ASCO) annual meeting doesn’t start for a few weeks, but a few companies made big moves on Thursday based on data in their abstracts that were released Wednesday evening. Here’s a breakdown of the pops and drops and a look at what to expect when ASCO kicks off on June 1.

Winner: Endocyte

Endocyte’s(NASDAQ:ECYT)data from....More>>>

Mid-Afternoon Market Update: Dow Turns Lower; J C Penney Shares Plunge

Toward the end of trading Thursday, the Dow traded down 0.16 percent to 24,729.12 while the NASDAQ declined 0.12 percent to 7,389.42. The S&P also fell, dropping 0.01 percent to 2,722.25.

Leading and Lagging Sectors

Thursday afternoon, the energy shares rose 1.16 percent. Meanwhile, top gainers in the sector included Seadrill Limited (NYSE: SDRL), up 33 percent, and Ultra Petroleum....More>>>

Your Daily Pharma Scoop: Loxo Outstanding Results, Cimzia Trial Success, Audentes Positive Data

Analysis focus: LOXO

Loxo Oncology (NASDAQ:LOXO), which was recently covered in a series of excellent articles by our very own Dr. Zach Hartman, PhD, who collaborates with the Total Pharma Tracker and whose members saw an early view of the series (…and so on), is up strongly following preliminary results which showed that its new LOXO-292 experimental cancer drug led to tumor shrinkage....More>>>

Mid-Day Market Update: Baozun Rises Following Q1 Results; Jounce Therapeutics Shares Plummet

Midway through trading Thursday, the Dow traded up 0.15 percent to 24,805.86 while the NASDAQ climbed 0.26 percent to 7,417.56. The S&P also rose, gaining 0.25 percent to 2,729.24.

Leading and Lagging Sectors

On Thursday, the energy shares rose 1.34 percent. Meanwhile, top gainers in the sector included Seadrill Limited (NYSE: SDRL), up 46 percent, and Sanchez Energy Corporation....More>>>

Your Daily Pharma Scoop: Loxo Outstanding Results, Cimzia Trial Success, Audentes Positive Data

Analysis focus: LOXO

Loxo Oncology (NASDAQ:LOXO), which was recently covered in a series of excellent articles by our very own Dr. Zach Hartman, PhD, who collaborates with the Total Pharma Tracker and whose members saw an early view of the series (…and so on), is up strongly following preliminary results which showed that its new LOXO-292 experimental cancer drug led to tumor shrinkage....More>>>

Ignyta: ROS1 Lung Cancer Update Causing Shares To Break Out

Shares of Ignyta (NASDAQ:RXDX) have more than doubled over the past year, with news in May that the company received the coveted Breakthrough Therapy Designation for entrectinib providing momentum for the next leg up.

RXDX data by YCharts

The drug candidate received the designation for the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumors in....More>>>

25 Stocks Moving In Monday's Pre-Market Session

Gainers Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate. Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination....More>>>